July 29, 2019 / 8:35 PM / a month ago

BRIEF-Crispr Therapeutics Posts Q2 Loss Per Share Of $1.01

July 30 (Reuters) - CRISPR Therapeutics AG:

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS

* CRISPR THERAPEUTICS AG - ENROLLING IN PHASE 1/2 CLINICAL TRIAL OF CTX110™, TARGETING CD19+ MALIGNANCIES

* QTRLY LOSS PER SHARE $1.01

* ENROLLMENT IN BOTH PHASE 1/2 STUDIES OF CTX001 IN PATIENTS WITH TDT AND IN PATIENTS WITH SEVERE SCD IS ONGOING

* EXPECTS TO OBTAIN PRELIMINARY SAFETY AND EFFICACY DATA IN LATE 2019 FROM PHASE 1/2 STUDIES OF CTX001 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below